A p38mapk-p53 cascade regulates mesodermal differentiation and neurogenesis of embryonic stem cells

Cell Death and Disease

Volumn 4, Issue 7, 2013, Pages

  Hadjal, Y ^a,b   Hadadeh, O ^a,b   Yazidi, C E L ^a,b   Barruet, E ^a,b   Binetruy B ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

Author keywords

Cardiomyogenesis; Mouse embryonic stem cells; Neurogenesis; P38MAPK; P53; Skeletal myogenesis

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN P53; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR PAX6;

ADIPOCYTE; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE REGULATION; CELL DIFFERENTIATION; DNA DAMAGE; EMBRYO; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENZYME REGULATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE REPRESSION; MESODERM; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; CELL DIFFERENTIATION; EMBRYONIC STEM CELLS; GENE EXPRESSION; HUMANS; MAP KINASE SIGNALING SYSTEM; MESODERM; MICE; NEURAL STEM CELLS; NEUROGENESIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84881052085     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.246     Document Type: Article

References (38)

1. Young RA. Control of the embryonic stem cell state. Cell 2011; 144: 940-954.
2. Kashyap V, Rezende N, Scotland K, Shaffer S, Persson J, Gudas L et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cell Dev 2009; 18: 1093-1108.
3. Wobus AM. Potential of embryonic stem cells. Mol Aspects Med 2001; 22: 149-164.
4. Wobus AM, Boheler KR. Embryonic stem cells: prospects for developmental biology and cell therapy. Physiol Rev 2005; 85: 635-678.
5. Wobus AM, Guan K, Yang HT, Boheler KR. Embryonic stem cells as a model to study cardiac, skeletal muscle, and vascular smooth muscle cell differentiation. Methods Mol Biol 2002; 185: 127-156.
6. Rohwedel J, Guan K, Wobus AM. Induction of cellular differentiation by retinoic acid in vitro. Cells Tissues Organs 1999; 165: 190-202.
7. Ying Q-L, Stavridis M, Griffiths D, Li M, Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol 2003; 21: 183-186.
8. Dani C, Smith AG, Dessolin S, Leroy P, Staccini L, Villageois P et al. Differentiation of embryonic stem cells into adipocytes in vitro. J Cell Sci 1997; 110 (Pt 11): 1279-1285.
9. Hescheler J, Fleischmann BK, Wartenberg M, Bloch W, Kolossov E, Ji G et al. Establishment of ionic channels and signalling cascades in the embryonic stem cell-derived primitive endoderm and cardiovascular system. Cells Tissues Organs 1999; 165: 153-164.
10. Barruet E, Hadadeh O, Peiretti F, Renault VM, Hadjal Y, Bernot D et al. p38 Mitogen activated protein kinase controls two successive-steps during the early mesodermal commitment of embryonic stem cells. Stem Cells Dev 2011; 20: 1233-1246.
11. Cuenda A, Cohen P. Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 1999; 274: 4341-4346.
12. Cuenda A, Rousseau S. p38 MAP-Kinases pathway regulation, function and role in human diseases. Biochimic Biophys Acta 2007; 1773: 1358-1375.
13. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, Karin M. Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 2000; 102: 221-231.
14. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S et al. Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 2000; 6: 109-116.
15. Aouadi M, Bost F, Caron L, Laurent K, Le Marchand Brustel Y, Binetruy B. p38 Mitogenactivated protein kinase activity commits embryonic stem cells to either neurogenesis or cardiomyogenesis. Stem Cells 2006; 24: 1399-1406.
16. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009; 137: 413-431.
17. Lin T, Chao C, Saito S, Mazur SJ, Murphy ME, Appella E et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol 2005; 7: 165-171.
18. Zhao T, Xu Y. p53 and stem cells: new developments and new concerns. Trends Cell Biol 2010; 20: 170-175.
19. Miyashita T, Harigai M, Hanada M, Reed JC. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 1994; 54: 3131-3135.
20. Wu Y, Mehew JW, Heckman CA, Arcinas M, Boxer LM. Negative regulation of bcl-2 expression by p53 in hematopoietic cells. Oncogene 2001; 20: 240-251.
21. Trouillas M, Saucourt C, Duval D, Gauthereau X, Thibault C, Dembele D et al. Bcl2, a transcriptional target of p38 alpha, is critical for neuronal commitment of mouse embryonic stem cells. Cell Death Differ 2008; 15: 1450-1459.
22. Komarov PG, Komarova EA, Kondratov RV, Christov-Tselkov K, Coon JS, Chernov MV et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 1999; 285: 1733-1737.
23. Bondue A, Lapouge G, Paulissen C, Semeraro C, Iacovino M, Kyba M et al. Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. Cell Stem Cell 2008; 3: 69-84.
24. Kishi H, Nakagawa K, Matsumoto M, Suga M, Ando M, Taya Y et al. Osmotic shock induces G1 arrest through p53 phosphorylation at Ser33 by activated p38MAPK without phosphorylation at Ser15 and Ser20. J Biol Chem 2001; 276: 39115-39122.
25. Huang C, Ma WY, Maxiner A, Sun Y, Dong Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J Biol Chem 1999; 274: 12229-12235.
26. Jain AK, Allton K, Iacovino M, Mahen E, Milczarek RJ, Zwaka TP et al. p53 regulates cell cycle and microRNAs to promote differentiation of human embryonic stem cells. PLoS Biol 2012; 10: e1001268.
27. Solozobova V, Rolletschek A, Blattner C. Nuclear accumulation and activation of p53 in embryonic stem cells after DNA damage. BMC Cell Biology 2009; 10: 46.
28. Aouadi M, Laurent K, Prot M, Le Marchand-Brustel Y, Binetruy B, Bost F. Inhibition of p38MAPK increases adipogenesis from embryonic to adult stages. Diabetes 55: 281-289.
29. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr., Butel JS et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
30. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR. High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 1995; 5: 931-936.
31. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T. A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 1995; 10: 175-180.
32. Almog N, Rotter V. Involvement of p53 in cell differentiation and development. Biochim Biophys Acta 1997; 1333: F1-27.
33. Nikoletopoulou V, Plachta N, Allen ND, Pinto L, Gotz M, Barde YA. Neurotrophin receptormediated death of misspecified neurons generated from embryonic stem cells lacking Pax6. Cell Stem Cell 2007; 1: 529-540.
34. Porrello A, Cerone MA, Coen S, Gurtner A, Fontemaggi G, Cimino L et al. p53 regulates myogenesis by triggering the differentiation activity of pRb. J Cell Biol 2000; 151: 1295-1304.
35. Molchadsky A, Shats I, Goldfinger N, Pevsner-Fischer M, Olson M, Rinon A et al. p53 plays a role in mesenchymal differentiation programs, in a cell fate dependent manner. PLoS One 2008; 3: e3707.
36. Zhu D, Qu L, Zhang X, Lou Y. Icariin-mediated modulation of cell cycle and p53 during cardiomyocyte differentiation in embryonic stem cells. Eur J Pharmacol 2005; 514: 99-110.
37. Ding L, Liang XG, Hu Y, Zhu DY, Lou YJ. Involvement of p38MAPK and reactive oxygen species in icariin-induced cardiomyocyte differentiation of murine embryonic stem cells in vitro. Stem Cells Dev 2008; 17: 751-760.
38. Bost F, Caron L, Marchetti I, Dani C, Le Marchand-Brustel Y, Binetruy B. Retinoic acid activation of the ERK pathway is required for embryonic stem cell commitment into the adipocyte lineage. Biochem J 2002; 361(Pt 3): 621-627.